Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Aldoxorubicin HCl,PD-L1 t-haNK
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : ImmunityBio
Deal Size : Undisclosed
Deal Type : Merger
Immunitybio and Nantkwest to Merge, Creating a Leading Immunotherapy and Cell Therapy Company
Details : The transaction is structured as a tax-free 100% stock-for-stock merger, with ImmunityBio to reverse merge with NantKwest. Following the closing of the transaction, the combined company will assume the ImmunityBio name and continue to be listed on the NA...
Product Name : INNO-206
Product Type : Cytotoxic Drug
Upfront Cash : Undisclosed
December 21, 2020
Lead Product(s) : Aldoxorubicin HCl,PD-L1 t-haNK
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : ImmunityBio
Deal Size : Undisclosed
Deal Type : Merger
Lead Product(s) : PD-L1 t-haNK,Aldoxorubicin HCl
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : ImmunityBio
Deal Size : Inapplicable
Deal Type : Inapplicable
NantKwest, ImmunityBio Add Third-Line Cohort to Phase 2 Pancreatic Cancer Trial
Details : Third cohort added to independently evaluate the efficacy of NantKwest’s PD-L1 t-haNK natural killer cells plus ImmunityBio’s IL-15 superagonist AnktivaÔ (N-803) in third-line or greater therapy for patients with locally advanced or metastatic pancr...
Product Name : PD-L1 t-haNK
Product Type : Vaccine
Upfront Cash : Inapplicable
June 10, 2020
Lead Product(s) : PD-L1 t-haNK,Aldoxorubicin HCl
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : ImmunityBio
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BM-Allo.MSC
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Preliminary data from NantKwest collaborators suggests mesenchymal stem cell treatments may benefit COVID-19 patients with acute respiratory distress syndrome and cytokine storm.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
May 18, 2020
Lead Product(s) : BM-Allo.MSC
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : PD-L1 t-haNK,Aldoxorubicin HCl
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : ImmunityBio
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Open-label, randomized Phase 2 study will evaluate combination immunotherapy, including NantKwest’s PD-L1 tumor-targeted natural killer cells and ImmunityBio’s IL-15 superagonist N-803 with standard of care versus standard of care alone.
Product Name : PD-L1 t-haNK
Product Type : Vaccine
Upfront Cash : Inapplicable
May 14, 2020
Lead Product(s) : PD-L1 t-haNK,Aldoxorubicin HCl
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : ImmunityBio
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : haNK
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : ImmunityBio
Deal Size : Undisclosed
Deal Type : Collaboration
NantKwest and ImmunityBio Announce Therapeutics and Vaccines for Combatting Covid-19
Details : Under this collaboration, NantKwest and ImmunityBio are combining their resources to design and develop therapeutics and vaccines for COVID-19.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
April 14, 2020
Lead Product(s) : haNK
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : ImmunityBio
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Clinical trial for patients failing checkpoint therapy uses combination of first-in-class, cryopreserved, CD16 NK cells, ImmunityBio’s IL-15 superagonist and checkpoint inhibitor Avelumab.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
March 19, 2020
NantKwest rockets on promising pancreatic cancer data
Details : Nantkwest received breakthrough therapy designation from FDA for N-803, IL -15 fusion protein for BCG-unresponsive non-muscle invasive bladder carcinoma in situ.
Product Name : N-803
Product Type : Protein
Upfront Cash : Inapplicable
January 16, 2020
Details : World’s first combination of tumor-targeted, off-the-shelf PD-L1-targeted Natural Killer cells with IL-15 fusion protein demonstrated complete response in metastatic pancreatic cancer.
Product Name : PD-L1.t-haNK
Product Type : Vaccine
Upfront Cash : Inapplicable
January 14, 2020
Reset All
